Cargando…

New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane

Aromatase inhibitor (AI) treatment is first-line systemic treatment for the majority of postmenopausal breast cancer patients with estrogen receptor (ER)-positive primary tumor. Although many patients benefit from treatment, some will develop resistance, and models mimicking acquired resistance will...

Descripción completa

Detalles Bibliográficos
Autores principales: HOLE, STINE, PEDERSEN, ASTRID M., HANSEN, SUSANNE K., LUNDQVIST, JOHAN, YDE, CHRISTINA W., LYKKESFELDT, ANNE E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356498/
https://www.ncbi.nlm.nih.gov/pubmed/25625755
http://dx.doi.org/10.3892/ijo.2015.2850
_version_ 1782361013423702016
author HOLE, STINE
PEDERSEN, ASTRID M.
HANSEN, SUSANNE K.
LUNDQVIST, JOHAN
YDE, CHRISTINA W.
LYKKESFELDT, ANNE E.
author_facet HOLE, STINE
PEDERSEN, ASTRID M.
HANSEN, SUSANNE K.
LUNDQVIST, JOHAN
YDE, CHRISTINA W.
LYKKESFELDT, ANNE E.
author_sort HOLE, STINE
collection PubMed
description Aromatase inhibitor (AI) treatment is first-line systemic treatment for the majority of postmenopausal breast cancer patients with estrogen receptor (ER)-positive primary tumor. Although many patients benefit from treatment, some will develop resistance, and models mimicking acquired resistance will be valuable tools to unravel the resistance mechanisms and to find new treatments and biomarkers. Cell culture models for acquired resistance to the three clinically relevant AIs letrozole, anastrozole and exemestane were developed by selection and expansion of colonies of MCF-7 breast cancer cells surviving long-term AI treatment under conditions where endogenous aromatase-mediated conversion of androgen to estrogen was required for growth. Four cell lines resistant to each of the AIs were established and characterized. Maintenance of ER expression and function was a general finding, but ER loss was seen in one of twelve cell lines. HER receptor expression was increased, in particular EGFR expression in letrozole-resistant cell lines. The AI-resistant cell lines had acquired ability to grow without aromatase-mediated conversion of testosterone to estradiol, but upon withdrawal of AI treatment, testosterone induced minor growth stimulation. Letrozole, exemestane and tamoxifen were able to abrogate the testosterone stimulation but could not reduce growth to below the level in standard growth medium with AI, demonstrating cross-resistance between letrozole, exemestane and tamoxifen. In contrast, fulvestrant totally blocked growth of the AI resistant cell lines both after withdrawal of AI and with AI treatment. These data show that ER is the main driver of growth of the AI-resistant cell lines and indicate ligand-independent activation of ER. Fulvestrant is an efficient treatment option for these AI-resistant breast cancer cells, and the cell lines will be useful tools to disclose the underlying molecular mechanism for resistance to the different AIs.
format Online
Article
Text
id pubmed-4356498
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-43564982015-03-18 New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane HOLE, STINE PEDERSEN, ASTRID M. HANSEN, SUSANNE K. LUNDQVIST, JOHAN YDE, CHRISTINA W. LYKKESFELDT, ANNE E. Int J Oncol Articles Aromatase inhibitor (AI) treatment is first-line systemic treatment for the majority of postmenopausal breast cancer patients with estrogen receptor (ER)-positive primary tumor. Although many patients benefit from treatment, some will develop resistance, and models mimicking acquired resistance will be valuable tools to unravel the resistance mechanisms and to find new treatments and biomarkers. Cell culture models for acquired resistance to the three clinically relevant AIs letrozole, anastrozole and exemestane were developed by selection and expansion of colonies of MCF-7 breast cancer cells surviving long-term AI treatment under conditions where endogenous aromatase-mediated conversion of androgen to estrogen was required for growth. Four cell lines resistant to each of the AIs were established and characterized. Maintenance of ER expression and function was a general finding, but ER loss was seen in one of twelve cell lines. HER receptor expression was increased, in particular EGFR expression in letrozole-resistant cell lines. The AI-resistant cell lines had acquired ability to grow without aromatase-mediated conversion of testosterone to estradiol, but upon withdrawal of AI treatment, testosterone induced minor growth stimulation. Letrozole, exemestane and tamoxifen were able to abrogate the testosterone stimulation but could not reduce growth to below the level in standard growth medium with AI, demonstrating cross-resistance between letrozole, exemestane and tamoxifen. In contrast, fulvestrant totally blocked growth of the AI resistant cell lines both after withdrawal of AI and with AI treatment. These data show that ER is the main driver of growth of the AI-resistant cell lines and indicate ligand-independent activation of ER. Fulvestrant is an efficient treatment option for these AI-resistant breast cancer cells, and the cell lines will be useful tools to disclose the underlying molecular mechanism for resistance to the different AIs. D.A. Spandidos 2015-01-26 /pmc/articles/PMC4356498/ /pubmed/25625755 http://dx.doi.org/10.3892/ijo.2015.2850 Text en Copyright © 2015, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
HOLE, STINE
PEDERSEN, ASTRID M.
HANSEN, SUSANNE K.
LUNDQVIST, JOHAN
YDE, CHRISTINA W.
LYKKESFELDT, ANNE E.
New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane
title New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane
title_full New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane
title_fullStr New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane
title_full_unstemmed New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane
title_short New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane
title_sort new cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356498/
https://www.ncbi.nlm.nih.gov/pubmed/25625755
http://dx.doi.org/10.3892/ijo.2015.2850
work_keys_str_mv AT holestine newcellculturemodelforaromataseinhibitorresistantbreastcancershowssensitivitytofulvestranttreatmentandcrossresistancebetweenletrozoleandexemestane
AT pedersenastridm newcellculturemodelforaromataseinhibitorresistantbreastcancershowssensitivitytofulvestranttreatmentandcrossresistancebetweenletrozoleandexemestane
AT hansensusannek newcellculturemodelforaromataseinhibitorresistantbreastcancershowssensitivitytofulvestranttreatmentandcrossresistancebetweenletrozoleandexemestane
AT lundqvistjohan newcellculturemodelforaromataseinhibitorresistantbreastcancershowssensitivitytofulvestranttreatmentandcrossresistancebetweenletrozoleandexemestane
AT ydechristinaw newcellculturemodelforaromataseinhibitorresistantbreastcancershowssensitivitytofulvestranttreatmentandcrossresistancebetweenletrozoleandexemestane
AT lykkesfeldtannee newcellculturemodelforaromataseinhibitorresistantbreastcancershowssensitivitytofulvestranttreatmentandcrossresistancebetweenletrozoleandexemestane